NCP14

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: NCP14
• 英文别名: 3-[4-[2-(N-pyridin-2-ylanilino)ethoxy]phenyl]propanoic acid
• 化学式: C₂₂H₂₂N₂O₃
• 分子量: 362.428
• InChiKey: PQKUQHHPEJJXHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-苯胺基吡啶 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 NCP14
  参考文献：
  名称：

  Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2

  摘要：

  To develop novel PPAR gamma ligands, we synthesized thirteen 3-{4-(2-aminoethoxy)phenyl}propanoic acid derivatives, which are designed based on the structures of rosiglitazone and 15d-PGJ(2). Among these compounds, compound 9 was found to be as potent as rosiglitazone in a binding assay and a preadipocyte differentiation test. Molecular modeling suggested that the nonyl group of 9 interacted with hydrophobic amino acid residues constructing the hydrophobic region of PPAR gamma protein where the alkyl chain of 15d-PGJ(2) is expected to be located. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.074

文献信息

• G-Protein-Conjugated Receptor Agonist
  申请人：Tsujimoto Gozoh

  公开号：US20110184031A1

  公开（公告）日：2011-07-28

  Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R 1 represents a C 1-6 alkyl group or the like; R 2 represents a hydrogen atom, a C 1-4 alkyl group or a C 1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or —NR 3 — [wherein R 3 represents a hydrogen atom or a C 1-4 alkyl group].

  本发明揭示了一种新型的芳基羧酸化合物，其具有对GPR-120和/或GPR-40，特别是GPR-120的激动活性，因此可用作食欲调节剂、抗肥胖剂、糖尿病治疗剂、胰岛素分化细胞生长增强剂、代谢综合征治疗剂、胃肠疾病治疗剂、神经病治疗剂、精神障碍治疗剂、肺部疾病治疗剂、垂体激素分泌障碍治疗剂或脂肪调味/调料剂。芳基羧酸化合物由通式（I）表示。其中，环Q表示吡啶基或类似物；R1表示C1-6烷基或类似物；R2表示氢原子、C1-4烷基或C1-4烷氧基；m和n独立地表示1至5的整数；X表示氧原子、硫原子或-NR3- [其中R3表示氢原子或C1-4烷基]。
• G-PROTEIN-CONJUGATED RECEPTOR AGONIST
  申请人：Japan Science and Technology Agency

  公开号：EP2151236A1

  公开（公告）日：2010-02-10

  Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or - NR3- [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

  本发明公开了一种新型芳烷基羧酸化合物，该化合物对 GPR-120 和/或 GPR-40（尤其是 GPR-120）具有激动活性，因此可用作食欲调节剂、抗肥胖剂、糖尿病治疗剂、胰腺β分化细胞生长促进剂、代谢综合征治疗剂、胃肠道疾病治疗剂、神经病治疗剂、精神疾病治疗剂、肺病治疗剂、垂体激素分泌紊乱治疗剂或脂质调味/调料剂。芳烷基羧酸化合物由通式 (I) 表示。(I) 其中环 Q 代表吡啶基或类似物；R1 代表 C1-6 烷基或类似物；R2 代表氢原子、C1-4 烷基或 C1-4 烷氧基；m 和 n 独立地代表 1 至 5 的整数；X 代表氧原子、硫原子或 - NR3-[其中 R3 代表氢原子或 C1-4 烷基]。
• US8318781B2
  申请人：——

  公开号：US8318781B2

  公开（公告）日：2012-11-27
• Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2
  作者：Shinya Usui、Takayoshi Suzuki、Yoshifumi Hattori、Kazuma Etoh、Hiroki Fujieda、Makoto Nishizuka、Masayoshi Imagawa、Hidehiko Nakagawa、Kohfuku Kohda、Naoki Miyata

  DOI：10.1016/j.bmcl.2005.01.074

  日期：2005.3

  To develop novel PPAR gamma ligands, we synthesized thirteen 3-4-(2-aminoethoxy)phenyl}propanoic acid derivatives, which are designed based on the structures of rosiglitazone and 15d-PGJ(2). Among these compounds, compound 9 was found to be as potent as rosiglitazone in a binding assay and a preadipocyte differentiation test. Molecular modeling suggested that the nonyl group of 9 interacted with hydrophobic amino acid residues constructing the hydrophobic region of PPAR gamma protein where the alkyl chain of 15d-PGJ(2) is expected to be located. (c) 2005 Elsevier Ltd. All rights reserved.